A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumours

Trial Profile

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumours

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Jan 2018

At a glance

  • Drugs Durvalumab (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Colorectal cancer; Gastric cancer; Glioblastoma; Head and neck cancer; Liver cancer; Malignant melanoma; Nasopharyngeal cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Urogenital cancer; Uveal melanoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 12 Jan 2018 Planned End Date changed from 13 Jul 2018 to 23 Apr 2020.
    • 15 Dec 2017 Results published in the Clinical Pharmacology and Therapeutics
    • 15 Dec 2017 Pooled data from two studies (NCT02087423 and NCT01693562 n=1,409 providing 7,407 PK samples) were analysed with non-linear mixed effects modelling, results published in the Clinical Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top